Clinical trial
The Efficacy and Safety of Allogenic Anti-CD19 CAR-T Cell Therapy for Refractory Graves' Disease
NCT07129642 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Allogenic Anti-CD19 CAR-T Cell Therapy for Refractory Graves' Disease
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 10, 2025
- Completion date
- March 31, 2027
- Enrollment
- 5 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.